[对阻塞性睡眠呼吸暂停的葡萄糖类-1受体激动剂的研究现状]
1Second Department of Respiratory and Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,China.
概括
类似葡萄糖类-1受体激动剂对阻塞性睡眠呼吸暂停 (OSA) 具有治疗潜力,这是一个常见的呼吸障碍,通常与2型糖尿病和肥胖有关. 这些药物有助于减肥,改善血糖控制,提供了一种新的治疗途径.
科学领域:
- 内分泌学 在内分泌学.
- 肺部病理学 肺部病理学
- 代谢疾病 代谢疾病
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 是一种普遍的睡眠障碍.
- 持续正气道压力 (CPAP) 是主要的治疗方法,但患者的坚持通常很差.
- OSA经常与2型糖尿病和肥胖症同时发生,使管理复杂化.
研究的目的:
- 探索OSA的新型治疗策略.
- 为了研究药物具有低血糖和减肥效应的作用.
- 讨论葡萄糖类-1受体激动剂在治疗OSA及其并发症方面的疗效.
主要方法:
- 关于葡萄糖类-1受体激动剂的治疗作用的文献综述.
- 对将体重减轻与OSA逆转相关的研究进行分析.
- 检查OSA和相关代谢条件的药理干预措施.
主要成果:
- 有效的减肥对于改善OSA和并发症至关重要.
- 仅仅是改变生活方式,往往无法实现持续的减肥.
- 类似葡萄糖-1受体激动剂显示出通过减肥和血糖控制来管理OSA的潜力.
结论:
- 类似葡萄糖类-1受体激动剂代表了对OSA的有希望的治疗途径.
- 这些药物可以治疗OSA及其常见的并发病,2型糖尿病和肥胖症.
- 对GLP-1受体激动剂的进一步研究可能会导致改善OSA治疗结果.
相关概念视频
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Hypoglycemia and Glucagon
260
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
260
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
GPCRs Regulate Adenylyl Cylase Activity
5.5K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K
Sedatives and Hypnotics Drugs: Miscellaneous Agents
172
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
172


